Food Allergen Immunotherapy in Preschool Children: Do We Have the Evidence?   [8-Aug-2023]

Loke P.; Vickery B.P.; Jones S.M.; Peters R.L.; Roberts G.; Koplin J.J.
Abstract Standard care for the management of food allergies previously centered on allergen avoidance and the treatment of adverse reactions after allergen exposure. An increase in the development of immunotherapy treatments for food allergy has occurred

Safety of COVID-19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi-centre cohort study.   [12-Aug-2022]

De Luca J.F.; Awad A.; Vogrin S.; Douglas A.P.; Lutjen A.; Gordon S.F.; Crawford N.W.; Barnes S. ; Trubiano J.A.

Clinical outcomes and characteristics of baked egg challenges in infants and children.   [24-Dec-2021]

Pitkin S.; Stevenson-Smith E.; Tomlin M.; Taranto M.; Loke P.
Abstract Background: Egg allergy is the most common food allergy in 12-monthold infants (8.9%). Previous studies have shown that about 70-80% of egg-allergic children can tolerate baked egg, which may improve quality of life through improved nutrition

Long-term longitudinal quality of life outcomes following a phase 2a open-label study of probiotic and peanut oral immunotherapy (PPOIT).   [9-Dec-2021]

Lloyd M.; Ashley S.; Hsiao K.; Pitkin S.; Dunn Galvin A.; Jayawardana K.; Lozinsky A.C.; Loke P.; Tang M.L.
Abstract was evaluated at screening (T0), end-of- treatment (T2), and 12-months (T4) and 3-years (T5) post-treatment, using the Food Allergy Quality of Life Questionnaire -Parent Form (FAQLQ-PF) and Food Allergy Impact Measure (FAIM). FAQLQ-PF total score and sub

The prevalence of IGE-mediated food allergy and other allergic diseases in the first 10 years: the population-based, longitudinal healthnuts study.   [11-Apr-2024]

Peters R.L.; Soriano V.X.; Allen K.J.; Tang M.L.K.; Perrett K.P.; Lowe A.J.; Wijesuriya R.; Parker K.M.; Loke P.; Dharmage S.C.; Koplin J.J.
Abstract Background: There are limited longitudinal data on the population prevalence of allergic conditions during childhood, and few studies have incorporated the reference standard oral food challenge to confirm food allergy. Objective(s): To describe

Interaction between baseline participant factors and treatment effects following peanut oral immunotherapy.   [5-Jan-2024]

Lloyd M.; Loke P.; Ashley S.; Lozinsky A.C.; Orsini F.; O'Sullivan M.; Gold M.; Quinn P.; Metcalfe J.; Tang M.L.
Abstract placebo-controlled food challenge, cumulative 4950mg peanut protein, at 8-weeks post-treatment) and HRQL (change in Food Allergy Quality of Life Questionnaire-Parent Form score). Interactions between baseline factors and treatment effects on remission

TreEAT trial: Protocol for a randomized controlled trial investigating the efficacy and safety of early introduction of tree nuts for the prevention of tree nut allergy in infants with peanut allergy.   [31-Mar-2023]

McWilliam V.L.; Koplin J.J.; Allen K.; Robinson M.; Smart J.; Loke P.; Peters R.L.; Dang T.; Lee K.J.; Dalziel K.; Tey D.; Taranto M.; Perrett K.P.
Abstract INTRODUCTION: Children with peanut allergy are at increased risk of developing tree nut allergies, which can be severe and for most lifelong. Introduction of peanut in the first year of life can reduce the risk of peanut allergy; however, prevention
Abstract to collate all investigations of the association between gender and total or subdomain HRQL scores of individuals with food allergy and their caregivers. Design(s): This is a narrative systematic review. We descriptively synthesised and compared HRQL outcomes
Title Clinical & Experimental Allergy
Title Expert Review of Clinical Immunology
Title Journal of Paediatrics and Child Health
Title J Paediatr Child Health
Title Paediatric Nursing skills for Australian Nurses